ICH E3 Clinical Study Report Template: Pick the Tier First, Then Defend the Section Map

At a glance

• A CSR template is a tiering decision before it is a table of contents. Decide full vs abbreviated vs synoptic from study importance and regulatory destination, then lay out the ICH E3 sections.
• ICH E3 (1995) defines the integrated full report and its 16-section structure; the section numbering and Appendix 16 sub-structure in this guide are attributed to ICH E3 itself.
• ICH E3 states abbreviated reports may be acceptable for uncontrolled studies, studies not designed to establish efficacy, and aborted or seriously flawed studies, but a controlled safety study should be reported in full and safety should always be described fully.
• Appendix 16 (the protocol, sample CRF, SAP documentation, randomization, audit certificate, patient data listings) is where reports actually fail completeness review.
• ICH E9(R1) requires that every analysis in the report be labeled pre-specified, introduced while still blinded, or post hoc. ICH E6(R3) requires that deviations from the planned statistical analysis and post-unblinding data changes be reported in the CSR. The CSR inherits the SAP; it does not get to quietly rewrite it.
• A “non-clinical study report” is not an ICH E3 CSR. This guide is for human clinical study reports only.

A clinical study report (CSR) is the document where a trial either holds together or falls apart under review. Most template pages reproduce the ICH E3 16-section list and stop. That is the wrong place to start. Before you open a section map you have to commit to a tier: a full integrated report, an abbreviated report, or a short synoptic report. The tier governs what you may legitimately leave out, and getting it wrong is the difference between a report that passes sponsor QC and survives a BIMO or EMA completeness review and one that triggers a deficiency letter. This guide decides the tier first, then defends the section and appendix map so the protocol → SAP → outputs → narrative traceability chain holds.

A note on scope and authority. The 16-section structure and the Appendix 16 sub-numbering below are taken from the ICH E3 guideline (Structure and Content of Clinical Study Reports, 1995), which is the controlling document for CSR format. Where this guide states what GCP, statistical, or quality requirements demand, it cites ICH E6(R3), ICH E9(R1), and ICH E8(R1) directly.

The CSR is a tiering decision first

ICH E3 describes the CSR as an “integrated” full report of an individual study, in which the clinical and statistical description, presentations, and analyses are integrated into a single report with appendices. ICH E3 is explicit that this integrated full report should not be derived by simply joining a separate clinical report and a separate statistical report. That is the default deliverable for a pivotal or otherwise important study.

ICH E3 then carves out when you may do less. Depending on the regulatory authority’s review policy, abbreviated reports using summarized data or with some sections deleted may be acceptable for uncontrolled studies or other studies not designed to establish efficacy, for seriously flawed or aborted studies, or for controlled studies that examine conditions clearly unrelated to those for which a claim is made. Two guardrails travel with that allowance. First, a controlled safety study should be reported in full. Second, a full description of safety aspects should be included even in an abbreviated report. ICH E3 also advises that if there is any question about whether a full report is needed, consult the regulatory authority. ICH E6(R3) §3.17.2 reinforces this from the GCP side: the sponsor should ensure clinical trial reports in marketing applications meet the standards of ICH E3, and it notes that ICH E3 specifies abbreviated reports may be acceptable in certain cases.

Use this to decide before you build:

Tier	Typical triggers	What it may legitimately drop	What it may never drop
Full integrated report	Pivotal/confirmatory study, controlled efficacy study, controlled safety study, anything supporting a claim	Nothing by tier; all 16 sections considered	Full efficacy and safety evaluation, integrated clinical + statistical content, Appendix 16 essential documents
Abbreviated report	Uncontrolled study, study not designed to establish efficacy, seriously flawed or aborted study, controlled study on conditions unrelated to the claim	Some sections deleted, summarized data in place of full analyses (per the reviewing authority’s policy)	A full description of safety aspects; enough design and result detail for the authority to judge whether a full report is needed
Synoptic / short report	Minor or supportive studies of limited importance; the synopsis-led short form	The depth of a full report (a less detailed report may be appropriate per study importance)	The synopsis content ICH E3 requires, including numerical data to illustrate results, not just text or p-values

The synoptic short report is the lightest form, anchored on the Section 2 synopsis. ICH E3 says the synopsis (usually limited to about three pages) should summarize the study and should include numerical data to illustrate results, not just text or p-values. Note that “abbreviated” and “synoptic” are tier judgments, not licenses to drop safety: the safety story is the one thing that survives every tier.

The ICH E3 section map (1–16)

The integrated full report is organized as 16 numbered sections. The map below is attributed to ICH E3; treat it as the skeleton every tier starts from and then prunes only as the tier allows.

§	Section	One-line purpose
1	Title Page	Study identity, sponsor, protocol ID, phase, dates, signatory, and a GCP-compliance statement including archiving of essential documents
2	Synopsis	Roughly 3-page summary with numerical results, not just text or p-values (load-bearing for the synoptic tier)
3	Table of Contents	Navigation for the report and its appendices
4	List of Abbreviations and Definitions	Controlled terminology for the report
5	Ethics	IEC/IRB review, ethical conduct, informed consent process
6	Investigators and Administrative Structure	Who ran the study and how it was governed
7	Introduction	One-page placement of the study in the development program
8	Study Objectives	The overall purpose(s) of the study
9	Investigational Plan	Design, population, treatments, randomization, blinding, endpoints
10	Study Patients	Disposition, protocol deviations
11	Efficacy Evaluation	Analysis sets, statistical methods, efficacy results (load-bearing)
12	Safety Evaluation	Exposure, adverse events, deaths/SAEs, labs, vital signs (load-bearing)
13	Discussion and Overall Conclusions	The integrated benefit–risk reading
14	Tables, Figures, and Graphs	In-text summary tables/figures referred to but not in the body
15	Reference List	Literature cited, per accepted citation standards
16	Appendices	The essential-document and data-listing chain (see below)

Sections 11 and 12 are where the report earns its keep. For Section 11, ICH E3 directs that the statistical analysis used be described for clinical and statistical reviewers in the text, with detailed documentation of statistical methods presented in Appendix 16.1.9, and that any changes in the analysis made after blind-breaking be identified. That last clause is not optional polish; it is the hook that ties Section 11 to the SAP-inheritance discipline below.

Appendix 16 is where CSRs fail completeness review

Most deficiency findings are not about prose in Sections 11–13. They are about a missing or incomplete appendix. ICH E3 prefaces Section 16 with a full list of all appendices and asks the applicant to clearly indicate which are submitted with the report; appendices available on request still have to be finalized by the time of filing. Use the checklist below; the sub-numbering is from ICH E3.

Tick	Appendix	Contents (per ICH E3)
☐	16.1.1	Protocol and protocol amendments
☐	16.1.2	Sample case report form (unique pages only)
☐	16.1.3	List of IECs/IRBs; representative patient information and sample consent forms
☐	16.1.4	List and description of investigators and key participants, with brief CVs
☐	16.1.5	Signatures of principal/coordinating investigator(s) or sponsor’s responsible medical officer
☐	16.1.6	Listing of patients receiving product from specific batches (if more than one batch)
☐	16.1.7	Randomization scheme and codes (patient ID and treatment assigned)
☐	16.1.8	Audit certificates (if available)
☐	16.1.9	Documentation of statistical methods
☐	16.1.10	Inter-laboratory standardization methods and QA procedures (if used)
☐	16.1.11 / 16.1.12	Publications based on the study; important referenced publications
☐	16.2	Patient data listings (discontinued patients, protocol deviations, demographics, AE listings, etc.)
☐	16.3	Case report forms (deaths, other SAEs, withdrawals for AE; other CRFs submitted)
☐	16.4	Individual patient data listings (US archival listings)

Two appendices recur as deficiency findings. Appendix 16.1.1 must contain the actual protocol and every amendment, because ICH E3 ties the design narrative in Section 9 back to it: the actual protocol and any changes should be included as Appendix 16.1.1. Appendix 16.1.7 must hold a detailed description of the randomization method, including how it was executed, plus a table of randomization codes, patient identifier, and treatment assigned. Where the sponsor used an independent internal or external auditing procedure, ICH E3 directs that audit certificates, if available, be provided in Appendix 16.1.8. Skipping these because they are “available on request” is the classic miss: ICH E3 still requires them finalized at filing.

Traceability that survives inspection

The reviewer is reconstructing a chain: protocol → SAP → TLF outputs → patient narratives. The CSR is where that chain is made visible, and the GCP and statistical guidelines put real obligations on it.

Start with the SAP. ICH E6(R3) §3.16.2 requires the sponsor to develop a statistical analysis plan consistent with the trial protocol, detailing the approach to data analysis, unless that approach is sufficiently described in the protocol. It also requires the sponsor to ensure the traceability of data transformations and derivations during data processing and analysis, and to ensure the criteria for inclusion or exclusion of participants from any analysis set are pre-defined, for example in the protocol or the SAP, with the rationale for any exclusion clearly documented. The CSR’s analysis sets and methods inherit those definitions; they are not authored fresh in the report.

The inheritance is enforced at reporting time. ICH E9(R1) §A.6 requires that results from the main, sensitivity, and supplementary analyses be reported systematically in the clinical trial report, specifying whether each analysis was pre-specified, introduced while the trial was still blinded, or performed post hoc. ICH E6(R3) §3.16.2 makes the same point operationally: post-unblinding data changes and deviations from the planned statistical analyses should be reported in the clinical trial report, and such deviations should only occur in exceptional circumstances. So every post-hoc analysis in your Section 11 must be labeled as such. A clean-looking efficacy table that silently mixes pre-specified and post-hoc analyses is not a stylistic lapse; it is a traceability failure that two separate guidelines independently require you to avoid.

These two guidelines align rather than conflict here, and it is worth saying so plainly: ICH E9(R1) defines the label set (pre-specified / blinded / post hoc), and ICH E6(R3) makes reporting the deviations in the CSR a GCP duty. They reinforce each other; there is no tension to reconcile.

The chain closes at the report itself. ICH E6(R3) §3.17.2 requires the sponsor to ensure that clinical trial reports, including interim reports, are prepared and provided to the regulatory authority as required, and that reports in marketing applications meet the standards of ICH E3. Where a coordinating investigator is involved, ICH E6(R3) says consideration should be given to them being a signatory on the report. The quality story rides along too: ICH E6(R3) §3.10 requires the sponsor to describe the quality management approach implemented in the trial in the CSR, and §3.10.1.6 requires important quality issues and the remedial actions taken to be summarized and reported in the CSR. ICH E8(R1) supplies the framing those sections document: quality by design means the quality of a study is driven proactively by designing quality into the protocol and processes, focusing on critical to quality factors. The CSR is where that designed-in quality is shown to have held.

Where teams get it wrong

• Treating the template as a fill-in form. Teams open a 16-section shell and start writing before deciding the tier. The result is an over-built abbreviated report or, worse, an “abbreviated” report that quietly drops safety content that ICH E3 says must always be described in full.
• Deferring Appendix 16 to the end. The 16.1.x essential documents, especially the protocol (16.1.1), randomization (16.1.7), audit certificates (16.1.8), and SAP documentation (16.1.9), are assembled last and arrive incomplete. ICH E3 requires on-request appendices to be finalized by filing, so “available on request” is not a deadline reprieve.
• Re-authoring the SAP inside the CSR. Analysis sets and methods get reworded in Section 11 in ways that drift from the SAP. ICH E6(R3) §3.16.2 requires pre-defined analysis-set criteria and documented, justified deviations; the report inherits the SAP, it does not replace it.
• Not labeling post-hoc analyses. Mixing exploratory or post-unblinding analyses with pre-specified ones without flags violates the explicit reporting requirement in ICH E9(R1) §A.6 and the deviation-reporting duty in ICH E6(R3) §3.16.2.
• Confusing a “non-clinical study report” with a CSR. The “non clinical study report template” search term refers to nonclinical/toxicology study reporting, which is a different deliverable governed by different guidance. It is not an ICH E3 CSR and is out of scope here. The synoptic short report, by contrast, is a tier of the human clinical study report, not a nonclinical document.

Pre-submission completeness checklist

• Tier decided and defensible: full, abbreviated, or synoptic, with the trigger (pivotal vs supportive, regulatory destination, terminated study) written down. Safety described in full regardless of tier.
• All 16 sections present (or consciously and documentably dropped under the tier rules), with a Section 2 synopsis carrying numerical results.
• Appendix 16 ticked end to end: 16.1.1 protocol + amendments, 16.1.2 sample CRF, 16.1.7 randomization scheme and codes, 16.1.8 audit certificate (if available), 16.1.9 SAP/statistical-methods documentation, 16.2–16.4 patient data listings, all finalized at filing.
• Every Section 11 analysis labeled pre-specified, blinded-stage, or post hoc; every deviation from the planned analysis and every post-unblinding data change reported and justified.
• Analysis sets traceable to pre-defined SAP/protocol criteria; data derivations traceable.
• Quality management approach and important quality issues with remedial actions described in the report.
• Signatory arrangements settled, including coordinating-investigator signature where applicable.

Build the tier judgment first and the section map second, and the report stops being a deadline-driven fill-in exercise and becomes what the reviewer is actually checking: a complete, traceable, integrated account of the study. Sibling guides on the statistical analysis plan, patient narratives, protocol deviations, and TMF essential documents go deeper on the individual links in that chain.

Sources

• ICH E3 Structure and Content of Clinical Study Reports (version 1995) — ICH. https://database.ich.org/sites/default/files/E3_Guideline.pdf
• ICH E6(R3) Good Clinical Practice (version r3, 2025) — ICH. https://www.ich.org/page/efficacy-guidelines
• ICH E9(R1) Statistical Principles for Clinical Trials, Addendum on Estimands and Sensitivity Analysis (version r1, 2019) — ICH.
• ICH E8(R1) General Considerations for Clinical Studies (version r1, 2021) — ICH.